Top

RPS FebriDx Lateral Flow Assay

Active

JA07314Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Department of Homeland Security's Office of Procurement Operations plans to issue a sole source contract to Rapid Pathogen Screening (RPS) Inc. for the completion and FDA validation of the RPS FebriDx Lateral Flow Assay (LFA). This diagnostic tool is being developed to rapidly screen symptomatic and asymptomatic individuals for infection, supporting timely triage and the government’s "detect-to-treat" strategy. The LFA aims to enhance early detection of biological threats, which will improve response efforts and provide significant benefits such as reducing unnecessary antibiotic use and associated resistance, while lowering diagnostic costs. The work includes continued development, testing, evaluation, and finalization of the assay prototype, ensuring the government maintains its capability to respond effectively to biological incidents. This sole source award is intended to enable DHS and its stakeholders, including the Directorate of Science and Technology’s Chemical and Biological Defense Division, to deploy a rapid, accurate point-of-care diagnostic test that supports post-exposure prophylaxis and timely treatment decisions. Although technical proposals will not be considered at this pre-award stage, organizations with relevant capabilities may submit statements of technical capability for potential competition consideration, at the government's discretion. The contract will be performed in Sarasota, Florida, with key contacts designated as the Contract Specialist Danette Williams and Contracting Officer Michael E. Jones based in Washington, DC.

General Info

DHS awards sole source contract to RPS for FDA validation of rapid pathogen screening assay.

Agency

Department Of Homeland Security → Contract Administration Svcs Division

NAICS

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Place of Performance

7727 Delainey Court, SARASOTA, FL, 34240-8440, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhasePresolicitation

PostedMar 7

Presolicitation

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Homeland Security → Contract Administration Svcs Division

Contacts2 people available

OfficeWASHINGTON, DC, 20528, USA

Organization / AgencyDepartment Of Homeland Security → Contract Administration Svcs Division

Office AddressWASHINGTON, DC, 20528, USA

Contacts

Danette WilliamsContract Specialist

contact@example.gov

+1 (555) 000-0000

Michael E. JonesContracting Officer

contact@example.gov

+1 (555) 000-0000

Full Description

The Department of Homeland Security (DHS), Office of Procurement Operations (OPO), intends to issue a sole source award for the completing and finalizing the development and U.S. Food and Drug Administration (FDA) validation of the RPS FebriDx Lateral Flow Assay (LFA) in support of the DHS Directorate of Science and Technology, Chemical and Biological Defense Division (CBD) to Rapid Pathogen Screening (RPS) Inc., 7727 Delainey Court, Sarasota, FL 34240-8440. The work to be performed will involve the continued development, test, evaluation, and final completion of the current prototype assay and will be used in triage for rapidly screening patients infected (symptomatic), as well as provide comfort to those who may believe they potentially have been exposed (symptomatic and asymptomatic) and who may need post-exposure prophylaxis. The RPS FebriDx LFA will mitigate the consequence of biological incidents through early detection and complement the Government's "detect-to-treat" approach by providing a new capability to DHS and its stakeholders that not only rapidly and accurately diagnoses patients at the point of care, but buys precious time for the delivery of requisite medical countermeasures. Therefore, this requested action to continue support to develop, test, evaluate, and complete the current prototype assay will ensure continuity of the Government's ability to mitigate the consequence of biological incidents. The services to be provided for this proposed sole source action will also offer a solution for the widespread over use of antibiotics (and the resulting increase in antibiotic resistance), and will significantly mitigate the current costs associated with making an accurate diagnosis so that effective treatment can be administered. Note 22: This pre-award synopsis is for informational purposes only. Technical proposals will not be considered, however technical capability statements may be submitted, only if your organization has the technical capabilities necessary to meet the above stated needs. If such documents are submitted, they may be reviewed for consideration to open this requirement up for competition. The determination to open up the requirement to competition is at the sole discretion of the Government. All submissions become the property of the Federal Government, and will not be returned. ?